Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.51 |
| ▸ | GCGR | P47871 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210423 | 0.93 | ADORA1 (0.51) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7211815 | 0.87 | MEN1 (0.54) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7210528 | 0.87 | ADORA1 (0.61) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7222483 | 0.82 | ADORA1 (0.75) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7210550 | 0.82 | ADORA1 (0.75) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7210257 | 0.82 | ADORA1 (0.51) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7216197 | 0.80 | MAPK14 (0.46) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7210183 | 0.78 | ADORA1 (0.50) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7210262 | 0.77 | NPC1 (0.51) | ADORA1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7210043 | 0.77 | MAPK14 (0.45) | ADORA1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| CN-1246858-A | Substituted pyrimidine compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |